A practical reference on LC-MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-17 and is reviewed periodically as new material appears.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
=== Muscle and fat tissue === Microwave burns show some similarities with electrical burns, as the tissue damage is deep rather than superficial. Adipose tissue shows less degree of damage than muscles and other water-rich tissues. (In contrast, radiant heat, contact burns and chemical burns damage subcutaneous adipose tissue to higher extent than deeper muscle tissue.) Full-thickness biopsy of the area between burned and unburned skin shows layers of more and less damaged tissue (tissue sparing), layers of undamaged fat between damaged muscles; a pattern that is not present in conventional thermal or chemical burns. Cells subjected to electrical burns show microscopic nuclear streaming on histology examination; this feature is not present with microwave burns. Microwaves also deposit more energy to areas with low blood supply and to tissue interfaces. Hot spots may be formed in the tissue, with a consequent higher absorption of microwave energy and even higher temperature achieved, with localized necrosis of the affected tissue following. Sometimes, the affected tissue can even be charred. Muscle tissue destruction can lead to myoglobinuria, with renal failure following in severe cases; this is similar to burns from electric current. Urinalysis and serum CPK, BUN and creatine tests are used to check for this condition.
The energy of various amounts of the explosive TNT (kiloton, megaton, gigaton) is often used as a unit of explosion energy, and sometimes of asteroid impacts and violent explosive volcanic eruptions. One ton of TNT produces 4.184×109 joules, or (by arbitrary definition) exactly 109 thermochemical calories (approximately 3.964×106 BTU). This definition is only loosely based on the actual physical properties of TNT.
=== Human data === PFOA is resistant to degradation by natural processes such as metabolism, hydrolysis, photolysis, or biodegradation and has been found to persist in the environment. PFOA is found in environmental and biological fluids as the anion perfluorooctanoate. PFOA can be absorbed from ingestion and can penetrate skin. The acid headgroup of PFOA enables binding to proteins with fatty acid or hormone substrates such as serum albumin, liver fatty acid-binding protein, and the nuclear receptors PPARα and possibly CAR. In animals, PFOA is mainly present in the liver, blood, and kidneys. PFOA does not accumulate in fat tissue, unlike traditional organohalogen persistent organic pollutants. In humans, PFOA has an average elimination half-life of about three years. Because of this long half-life, PFOA has the potential to bioaccumulate. The levels of PFOA exposure in humans vary widely. While an average American might have 3 or 4 parts per billion of PFOA present in their blood serum, individuals occupationally exposed to PFOA have had blood serum levels over 100,000 parts per billion (100 parts per million or 0.01%) recorded. While no amount of PFOA in humans is legally recognized as harmful, DuPont was "not satisfied" with data showing their Chinese workers accumulated an average of about 2,250 parts per billion of PFOA in their blood from a starting average of around 50 parts per billion less than a year prior.
=== Taxes === During his 2022 gubernatorial campaign, Moore repeatedly said that he did not anticipate raising taxes as governor, but said in September 2022 that he planned to work with the legislature to fix what he described as the state's "upside-down taxation system". In January 2024, he expressed openness to raising taxes to address the state's budget shortfall, but said that any conversation about taxes would have a "very high bar". That year, the legislature amended Moore's budget proposal, which included no tax increases, to add about $252 million in increases toward transportation-related fees and tobacco taxes to help pay for the Blueprint for Maryland's Future reforms and state transportation projects. In May 2022, following a spike in gas prices as a result of the Russo-Ukrainian War, Moore said he supported staving off automatic increases to the state's gas tax, arguing that voters needed immediate relief and later calling it a "regressive tax". He also expressed interest in eliminating either the state's estate or inheritance tax to make the state more attractive to retirees. In June 2023, Moore said he supported shifting transportation funding away from the state's gas tax as well as decoupling it from inflation, but opposed calling a special session to do so, instead preferring to pass tax reforms during the 2024 legislative session. In March 2026, Moore opposed a Republican proposal to implement a 30-day gas tax holiday following a spike in gas prices as a result of the 2026 Iran war.
Sources: en.wikipedia.org
== Chemistry == Dextromoramide is the right-handed isomer of the moramide molecule. The left-handed molecule is called levomoramide, and a mixture of the two is called racemoramide. Its full chemical name is (+)-1-(3-Methyl-4-morpholino-2,2-diphenylbutyryl)pyrrolidine, and its molecular formula: C25H32N2O2, with an atomic weight of ~392.5. Dextromoramide was discovered during the course of research into a related family of compounds, the α,α-Diphenyl-γ-Dialkyamino-Butyramides, which show no analgesic activity, but are extremely active physiologically as inhibitors of gastric secretions in man. Other drugs from this series show antispasmodic and antihistamine effects, but most research was put into researching analgesics. The structure-activity relationships of this family of drugs was investigated extensively, with dextromoramide representing the optimisation of several different structural features; (i) at the 1-amide group only the pyrrolidine and dimethylamide substituents were active, with pyrrolidine being more potent (ii) the alkyl chain was more potent when methylated, 3-methylation was more potent than 4-methylation, and in the 3-methyl analogues the dextro isomer was more active (iii) while morpholine, dimethylamine, pyrrolidine and piperidine were all active at the 4-amine group, morpholine was the most active (iv) any substitution on the phenyl rings reduces activity.
== History == Levodopa was first synthesized in 1911 by Torquato Torquati from the Vicia faba bean. It was first isolated in 1913 by Marcus Guggenheim from the V. faba bean. Guggenheim tried levodopa at a dose of 2.5 g and thought that it was inactive aside from nausea and vomiting. In work that earned him a Nobel Prize in 2000, Swedish scientist Arvid Carlsson first showed in the 1950s that administering levodopa to animals with drug-induced (reserpine) Parkinsonian symptoms caused a reduction in the intensity of the animals' symptoms. In 1960 or 1961 Oleh Hornykiewicz, after discovering greatly reduced levels of dopamine in autopsied brains of patients with Parkinson's disease, published together with the neurologist Walther Birkmayer dramatic therapeutic antiparkinson effects of intravenously administered levodopa in patients. This treatment was later extended to manganese poisoning and later parkinsonism by George Cotzias and his coworkers, who used greatly increased oral doses, for which they won the 1969 Lasker Prize. The first study reporting improvements in patients with Parkinson's disease resulting from treatment with levodopa was published in 1968. Levodopa was first marketed in 1970 by Roche under the brand name Larodopa. The neurologist Oliver Sacks describes this treatment in human patients with encephalitis lethargica in his 1973 book Awakenings, upon which the 1990 movie of the same name is based. Carbidopa was added to levodopa in 1974 and this improved its tolerability.
== Research == Bifidobacterium animalis subspecies lactis BB-12 administered in combination with other probiotics has shown "a trend toward increased remission" in a study of 32 patients with ulcerative colitis. Research on Bifidobacterium animalis supplementation in preterm infants, as detailed in the systematic review by Szajewska et al., a meta-analysis of four randomized controlled trials (RCTs) involving a total of 324 infants, has shown promising results. These include increased fecal bifidobacteria counts, reduced Enterobacteriaceae and Clostridium spp counts, as well as improvements in stool pH, fecal calprotectin concentrations, fecal immunoglobulin A levels, and short-chain fatty acid concentrations. However, the analysis did not find significant effects on the risk of necrotizing enterocolitis stage ≥2, risk of sepsis, or use of antibiotics compared to controls.
Sources: en.wikipedia.org
A nuclear isomer is a metastable state of an atomic nucleus in which one or more nucleons (protons or neutrons) occupy excited state levels (higher energy levels). "Metastable" describes nuclei whose excited states have half-lives of 10−9 seconds or longer, 100 to 1000 times longer than the half-lives of the excited nuclear states that decay with a "prompt" half-life (ordinarily on the order of 10−12 seconds). Some references recommend using a threshold of 5×10−9 seconds to distinguish the metastable half-life from the normal "prompt" gamma-emission half-life. The half-lives of a number of isomers are far longer than this and may be minutes, hours, or years. The most extreme example known is the 180m73Ta nuclear isomer, which survives so long (at least 2.9×1017 years) that it has never been observed to decay spontaneously, and occurs naturally as a primordial nuclide, though uncommonly at only 1/8000 of all tantalum. The second most stable isomer is 210m83Bi, which does not occur naturally; its half-life is 3.04×106 years to alpha decay. The half-life of a nuclear isomer can exceed that of the ground state of the same nuclide, as with the two above, as well as, for example, 186m75Re, 192m277Ir, 212m84Po, 242m95Am and multiple holmium isomers.
==== Electrolyte recycling ==== Electrolyte recycling consists of two phases. The collection phase extracts the electrolyte from the spent Li-ion battery. This can be achieved through mechanical processes, distillation, freezing, solvent extraction, and supercritical fluid extraction. Due to the volatility, flammability, and sensitivity of the electrolyte, the collection process poses a greater difficulty than the collection process for other components of a Li-ion battery. The next phase consists of separation/electrolyte regeneration. Separation consists of isolating the individual components of the electrolyte. This approach is often used for the direct recovery of the Li salts from the organic solvents. In contrast, regeneration of the electrolyte aims to preserve the electrolyte composition by removing impurities which can be achieved through filtration methods. The recycling of the electrolytes, which consists 10–15 wt.% of the Li-ion battery, provides both economic and environmental benefits. These benefits include the recovery of the valuable Li-based salts and the prevention of hazardous compounds, such as volatile organic compounds (VOCs) and carcinogens, being released into the environment. Compared to electrode recycling, less focus is placed on recycling the electrolyte of Li-ion batteries due to lower economic benefits and greater process challenges.
On 19 January it became known that Canada considered sending troops to Greenland to reinforce Danish sovereignty. Despite Poland's recent interest and participation in military exercises in the Arctic region, and having signed a bilateral defence agreement with Denmark in the 1990s, Polish prime minister Donald Tusk and Defence Minister Władysław Kosiniak-Kamysz stated that Poland would not deploy troops in Greenland. This decision was criticised by former Major General Roman Polko as "sheer cowardice", to which Kosiniak-Kamysz defended it as protecting NATO unity. Between 19 January and 3 February, NORAD deployed their aircraft to Pituffik Space Base in Greenland for long-planned activities, describing the deployment as routine and coordinated with the Kingdom of Denmark with diplomatic clearances and with the Government of Greenland informed of the planned operations. On 21 January, France proposed a larger NATO exercise in Greenland and said they are willing to participate.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.